MyOme

MyOme operates at the intersection of genetics, bioinformatics, and clinical care, offering a comprehensive whole-genome-based testing platform. Its core innovation is the integrated Polygenic Risk Score (iPRS™), which combines monogenic and polygenic risk data validated across diverse ancestries. The company targets multiple customer segments, including providers, patients, employers, and healthcare systems, with a focus on making precision medicine actionable in primary care settings. MyOme is a private, commercial-stage company with key partnerships, such as with Illumina and Broad Clinical Labs, enhancing its technological and distribution capabilities.

Clinical whole genome sequencing and analysis platform featuring proprietary integrated Polygenic Risk Scores (iPRS™) that combine monogenic and polygenic data, validated across diverse ancestries.

MyOme competes with large commercial labs (e.g., Labcorp, Quest), specialized genetic testing companies (e.g., Invitae, Ambry Genetics, Color), and academic medical center labs. Its primary differentiation is the clinical application of integrated polygenic risk scores from whole genome data, validated for diverse ancestries, within a provider-focused workflow.